Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TSH Biopharm Corporation Limited
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are 20-80 years of age
Patients with essential hypertension (90 mmHg ≤ DBP ≤ 110 mmHg and/or 140 mmHg ≤ SBP ≤ 180 mmHg) whose BP is not adequately controlled with amlodipine (or another CCB) alone or with valsartan (or another ARB) alone, or with any antihypertensive monotherapy.
Agree to and are able to follow the study procedures
Understand the nature of the study, and have signed informed consent forms
You may not be if
Patients with any of the following conditions:
1. Malignant (or history of malignant) hypertension
2. Secondary hypertension
3. Severe hypertension (mean sitting DBP ≥ 110 mmHg and/or mean sitting SBP ≥ 180 mmHg)
4. A history of hypertensive encephalopathy or cerebrovascular accident
5. Cerebrovascular accident, myocardial infraction within 3 months, or any type of revascularization
6. New York Heart Association class III -IV congestive heart failure
7. Second- or third-degree heart block
8. Angina pectoris
9. Significant arrhythmia or valvular heart disease
10. Significant pancreatic, hepatic, or renal disease
11. Diabetes requiring insulin treatment or poorly controlled type 2 diabetes
Patients with known contraindication or a history of allergy to CCBs or ARBs.
Female patients who are pregnant or lactating.
Male or female patients of child-bearing potential who do not agree to use an effective method of contraception during the study
Patients is currently participating in any other clinical trial within 30 days
Clareo Health | PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
